PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
187.54%
Cash & equivalents yoy growth at least 1.5x AGEN's 97.16%. Mohnish Pabrai might see this as a favorable liquidity edge, provided funds are well deployed.
No Data
No Data available this quarter, please select a different quarter.
187.23%
Cash + STI yoy ≥ 1.5x AGEN's 97.16%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
168.93%
≥ 1.5x AGEN's 99.56%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-20.60%
≥ 1.5x AGEN's -1.96%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.19%
Below half of AGEN's 0.98%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
164.96%
≥ 1.5x AGEN's 57.42%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-45.35%
Less than half of AGEN's 132.21%. David Dodd sees a more disciplined AP approach or lower volume.
-33.08%
Less than half of AGEN's -66.29%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
43.64%
Below half of AGEN's 5098.02%. Michael Burry suspects a big gap in pre-sales traction.
-68.51%
Less than half of AGEN's 1262.03%. David Dodd sees fewer expansions in other current obligations.
-61.96%
Less than half of AGEN's 127.52%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-61.96%
Less than half of AGEN's 37.97%. David Dodd sees far fewer liability expansions relative to competitor.
19.13%
1.25-1.5x AGEN's 12.94%. Martin Whitman sees potential dilution risk vs. competitor approach.
-3.37%
1.25-1.5x AGEN's -2.71%. Bruce Berkowitz notes stronger reinvestment strategy.
-26.34%
Less than half of AGEN's 38.79%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
955.36%
≥ 1.5x AGEN's 100.97%. David Dodd sees stronger capital base growth than competitor.
164.96%
≥ 1.5x AGEN's 57.42%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-33.08%
Less than half of AGEN's 90.86%. David Dodd sees less overall debt expansion vs. competitor.
-197.28%
Above 1.5x AGEN's -98.27%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.